January 23, 2019 - 7:30pm
Davos, Switzerland
Carolyn Rodriguez
Department of Psychiatry and Behavioral Sciences
Stanford University
Background
Low doses of ketamine seem able to dramatically improve obsessive-compulsive disorder, which has so far proved hard to treat. Carolyn Rodriguez’s lab at Stanford is seeking to understand how it works, with the hope of developing next-generation treatments that do not have ketamine’s side effects.
